LENZ · Company research
LENZ Therapeutics, Inc. Common Stock (LENZ): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| LENZ Oct 2026 10.000 put (LENZ261016P00010000) Stock Historical Prices & Data - Yahoo! Finance Canada | LENZ Oct 2026 10.000 put (LENZ261016P00010000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| LENZ Oct 2026 12.500 put (LENZ261016P00012500) stock historical prices and data - Yahoo Finance UK | LENZ Oct 2026 12.500 put (LENZ261016P00012500) stock historical prices and data Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 17, 2026 | neutral | 0 | 0.6 |
| LENZ270319C00020000 Interactive Stock Chart | LENZ Mar 2027 20.000 call Stock - Yahoo Finance | LENZ270319C00020000 Interactive Stock Chart | LENZ Mar 2027 20.000 call Stock Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| LENZ Jan 2027 25.000 call (LENZ270115C00025000) interactive stock chart - Yahoo Finance UK | LENZ Jan 2027 25.000 call (LENZ270115C00025000) interactive stock chart Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 17, 2026 | neutral | 0 | 0.6 |
| LENZ270319P00002500 Interactive Stock Chart | LENZ Mar 2027 2.500 put Stock - Yahoo Finance | LENZ270319P00002500 Interactive Stock Chart | LENZ Mar 2027 2.500 put Stock Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| Insiders Re-Evaluate Their US$654.9k Stock Purchase As LENZ Therapeutics Falls To US$113m - Simply Wall Street | Insiders Re-Evaluate Their US$654.9k Stock Purchase As LENZ Therapeutics Falls To US$113m Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions - Simply Wall Street | LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 504% Upside - TradingView | LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $22, Implies 504% Upside TradingView | View source ↗ | TradingView | Oct 10, 2026 | neutral | 0 | 0.6 |
| LENZ Jan 2027 5.000 put (LENZ270115P00005000) stock price, news, quote and history - Yahoo Finance UK | LENZ Jan 2027 5.000 put (LENZ270115P00005000) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics (LENZ) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | LENZ Therapeutics (LENZ) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| LENZ Oct 2026 7.500 call (LENZ261016C00007500) interactive stock chart - Yahoo Finance UK | LENZ Oct 2026 7.500 call (LENZ261016C00007500) interactive stock chart Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ | Pomerantz LLP is investigating potential securities fraud claims against LENZ Therapeutics following disappointing Q2 2026 earnings. The company reported flat organic product sales of $1.73 million for its primary eye drop VIZZ, with most revenue ($3.8M of $5.5M total) coming from one-time licensing milestones. Bank of America subsequently downgraded the stock from 'Buy' to 'Neutral' and slashed its price target from $31 to $7, citing slower-than-expected commercial launch performance. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts - Yahoo Finance | LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics (LENZ) Stock Reflects Loss Fatigue Despite Long Cash Runway - Simply Wall Street | LENZ Therapeutics (LENZ) Stock Reflects Loss Fatigue Despite Long Cash Runway Simply Wall Street | View source ↗ | Simply Wall Street | Aug 13, 2026 | neutral | 0 | 0.6 |
| Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ) - Seeking Alpha | Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 13, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - LENZ Therapeutics | LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights LENZ Therapeutics | View source ↗ | LENZ Therapeutics | Aug 11, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside - TradingView | LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside TradingView | View source ↗ | TradingView | Aug 11, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions - Yahoo Finance | LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions Yahoo Finance | View source ↗ | Yahoo Finance | Jul 11, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - LENZ Therapeutics | LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights LENZ Therapeutics | View source ↗ | LENZ Therapeutics | May 11, 2026 | neutral | 0 | 0.6 |
| LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - LENZ Therapeutics | LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights LENZ Therapeutics | View source ↗ | LENZ Therapeutics | Mar 24, 2026 | neutral | 0 | 0.6 |
| Why Lenz Therapeutics Stock Crashed Today - Yahoo Finance | Why Lenz Therapeutics Stock Crashed Today Yahoo Finance | View source ↗ | Yahoo Finance | Mar 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.